Literature DB >> 9674665

Mortality of women with polycystic ovary syndrome at long-term follow-up.

T Pierpoint1, P M McKeigue, A J Isaacs, S H Wild, H S Jacobs.   

Abstract

Metabolic disturbances associated with insulin resistance are present in most women with polycystic ovary syndrome. This has led to suggestions that women with polycystic ovary syndrome may be at increased risk of cardiovascular disease in later life. We undertook a long-term follow-up study to test whether cardiovascular mortality is increased in these women. A total of 786 women diagnosed with polycystic ovary syndrome in the United Kingdom between 1930 and 1979 were traced from hospital records and followed for an average of 30 years. Standardized mortality ratios (SMRs) were calculated to compare the death rates of these women with national rates. The SMR for all causes was 0.90 (95% CI, 0.69-1.17), based on 59 deaths. There were 15 deaths from circulatory disease, yielding an SMR of 0.83 (95% CI, 0.46-1.37). Of these 15 deaths, 13 were from ischemic heart disease (SMR 1.40; 95% CI, 0.75-2.40) and two were from other circulatory disease (SMR 0.23; 95% CI, 0.03-0.85). There were six deaths from diabetes mellitus as underlying or contributory cause, compared with 1.7 expected (odds ratio 3.6; 95% CI, 1.5-8.4). Breast cancer was the commonest cause of death (SMR 1.48 based on 13 deaths; 95% CI, 0.79-2.54). We conclude that women with polycystic ovary syndrome do not have markedly higher than average mortality from circulatory disease, even though the condition is strongly associated with diabetes, lipid abnormalities, and other cardiovascular risk factors. The characteristic endocrine profile of women with polycystic ovary syndrome may protect against circulatory disease in this condition.

Entities:  

Mesh:

Year:  1998        PMID: 9674665     DOI: 10.1016/s0895-4356(98)00035-3

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


  66 in total

Review 1.  Insulin resistance and polycystic ovary syndrome.

Authors:  David A Ehrmann
Journal:  Curr Diab Rep       Date:  2002-02       Impact factor: 4.810

Review 2.  [Polycystic ovary syndrome. Prototype of a cardio-metabolic syndrome].

Authors:  D Heutling; H Schulz; H Randeva; C Dodt; H Lehnert
Journal:  Internist (Berl)       Date:  2007-02       Impact factor: 0.743

3.  Long term health consequences of polycystic ovarian syndrome: a review analysis.

Authors:  A Daniilidis; K Dinas
Journal:  Hippokratia       Date:  2009-04       Impact factor: 0.471

4.  Polycystic ovary syndrome (PCOS): metformin.

Authors:  David J Cahill; Katherine O'Brien
Journal:  BMJ Clin Evid       Date:  2015-03-27

Review 5.  Adverse Pregnancy Conditions, Infertility, and Future Cardiovascular Risk: Implications for Mother and Child.

Authors:  Ki Park; Janet Wei; Margo Minissian; C Noel Bairey Merz; Carl J Pepine
Journal:  Cardiovasc Drugs Ther       Date:  2015-08       Impact factor: 3.727

6.  Long and irregular menstrual cycles, polycystic ovary syndrome, and ovarian cancer risk in a population-based case-control study.

Authors:  H R Harris; L J Titus; D W Cramer; K L Terry
Journal:  Int J Cancer       Date:  2016-10-06       Impact factor: 7.396

Review 7.  PCOS.

Authors:  David Cahill
Journal:  BMJ Clin Evid       Date:  2009-01-15

Review 8.  Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications.

Authors:  Evanthia Diamanti-Kandarakis; Andrea Dunaif
Journal:  Endocr Rev       Date:  2012-10-12       Impact factor: 19.871

Review 9.  Mediators of inflammation in polycystic ovary syndrome in relation to adiposity.

Authors:  Thozhukat Sathyapalan; Stephen L Atkin
Journal:  Mediators Inflamm       Date:  2010-04-08       Impact factor: 4.711

10.  Serum C-reactive protein levels in normal-weight polycystic ovary syndrome.

Authors:  Ji Young Oh; Ji-Ah Lee; Hyejin Lee; Jee-Young Oh; Yeon-Ah Sung; Hyewon Chung
Journal:  Korean J Intern Med       Date:  2009-11-27       Impact factor: 2.884

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.